Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 study of propofol + alfentanil + lidocaine for suppressing body movement during ocular regional block
ChiCTR2500095627Phase 4Not yet recruiting
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of propofol, alfentanil and lidocaine in None, sponsored by Zhongshan Ophthalmic Center. Primary endpoints: Ramsay sedation score and motor response during ocular block after 1 minute and Median effective dose (ED50). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
propofolalfentanillidocaine
Beyond the preview
Go deeper on ChiCTR2500095627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095627.